{{Drugbox
| verifiedrevid = 443395414
| IUPAC_name = {3-[2,3-dihydro-1''H''-inden-2-yl(phenyl)amino]propyl}diethylamine
| image = Aprindine.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|aprindine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL         / P       / POM / CD -->
| legal_US = <!-- OTC                   / Rx-only  -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 37640-71-4
| ATC_prefix = C01
| ATC_suffix = BB04
| PubChem = 2218
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01429
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2132
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5Y48085P9Q
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02969
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1213033
<!--Chemical data-->
| C=22 | H=30
| N=2
| molecular_weight = 322.487 g/mol
| smiles = c1cccc3c1CC(N(c2ccccc2)CCCN(CC)CC)C3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NZLBHDRPUJLHCE-UHFFFAOYSA-N
}}
'''Aprindine''' is a Class 1b [[antiarrhythmic agent]].<ref name="pmid1660104">{{cite journal |vauthors=Sato R, Hisatome I, Tanaka Y |title=Aprindine blocks the sodium current in guinea-pig ventricular myocytes |journal=Naunyn Schmiedebergs Arch. Pharmacol. |volume=344 |issue=3 |pages=331–6 |date=September 1991 |pmid=1660104 |doi= 10.1007/bf00183008|url=|display-authors=etal}}</ref>

In one study, it delayed [[atrial fibrillation]] more than [[digoxin]] did.<ref name="pmid12074271">{{cite journal |vauthors=Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H |title=Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation |journal=Circ. J. |volume=66 |issue=6 |pages=553–6 |date=June 2002 |pmid=12074271 |doi= 10.1253/circj.66.553|url=http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/66.553?from=PubMed|archive-url=https://archive.is/20121219035343/http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/66.553?from=PubMed|dead-url=yes|archive-date=2012-12-19}} </ref>

It has shown effectiveness when given orally.<ref name="pmid603737">{{cite journal |vauthors=Reid PR, Greene HL, Varghese PJ |title=Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome |journal=Br Heart J |volume=39 |issue=12 |pages=1353–60 |date=December 1977 |pmid=603737 |pmc=483421 |doi= 10.1136/hrt.39.12.1353|url=http://heart.bmj.com/cgi/pmidlookup?view=long&pmid=603737}}</ref>

==References==
{{reflist}}

{{Antiarrhythmic agents}}

[[Category:Antiarrhythmic agents]]
[[Category:Sodium channel blockers]]
[[Category:Indanes]]
[[Category:Amines]]

{{Amine-stub}}
{{cardiovascular-drug-stub}}